HMPL-306

DRUG4 trials

Sponsors

Hutchison Medipharma Limited, Hutchmed

Conditions

Acute Myeloid LeukemiaGliomas Harboring IDH1 and/or IDH2 MutationsIsocitrate Dehydrogenase Gene Mutation

Phase 1

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Hutchison Medipharma LimitedAcute Myeloid Leukemia

Start: 2020-05-14End: 2022-12-30Target: 75Updated: 2020-06-16

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

TerminatedNCT04762602

HutchmedIsocitrate Dehydrogenase Gene Mutation

Start: 2021-02-28End: 2025-02-27Updated: 2026-03-27

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

TerminatedNCT04764474

HutchmedIsocitrate Dehydrogenase Gene Mutation

Start: 2021-04-12End: 2025-01-15Updated: 2026-01-29

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

RecruitingNCT07025018

HutchmedGliomas Harboring IDH1 and/or IDH2 Mutations

Start: 2025-07-15End: 2027-12-31Target: 52Updated: 2025-08-01

Related Papers

Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.

Journal of Clinical Oncology2025-05-281 citations

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.

2025-01-312 citations

P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS

HemaSphere2023-08-012 citations

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

Blood2021-11-053 citations

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

HemaSphere2021-06-0112 citations